Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Madeddu, G., Menzaghi, B., Ricci, E., Carenzi, L., Martinelli, C., Di Biagio, A., et al. (2012). Raltegravir central nervous system tolerability in clinical practice: Results from a multicenter observational study. AIDS, 26(18), 2412-2415 [10.1097/QAD.0b013e32835aa141].
Raltegravir central nervous system tolerability in clinical practice: Results from a multicenter observational study
Bonfanti P.
2012
Abstract
Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.